Handelsbanken Fonder AB Has $4.65 Million Position in Bristol-Myers Squibb Company (BMY)

Handelsbanken Fonder AB lowered its position in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 26.0% during the first quarter, according to its most recent filing with the SEC. The fund owned 85,560 shares of the biopharmaceutical company’s stock after selling 30,000 shares during the period. Handelsbanken Fonder AB’s holdings in Bristol-Myers Squibb were worth $4,653,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the stock. American National Bank boosted its stake in shares of Bristol-Myers Squibb by 36.0% in the first quarter. American National Bank now owns 1,919 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 508 shares during the last quarter. Welch Investments LLC raised its position in Bristol-Myers Squibb by 3.9% in the first quarter. Welch Investments LLC now owns 2,109 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 79 shares during the period. Crestwood Advisors Group LLC acquired a new position in Bristol-Myers Squibb during the first quarter valued at about $116,000. State of Alaska Department of Revenue raised its position in Bristol-Myers Squibb by 2.8% in the first quarter. State of Alaska Department of Revenue now owns 2,229 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 60 shares during the period. Finally, Prentiss Smith & Co. Inc. raised its position in Bristol-Myers Squibb by 61.8% in the first quarter. Prentiss Smith & Co. Inc. now owns 2,333 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 891 shares during the period. 69.56% of the stock is currently owned by institutional investors.

Shares of Bristol-Myers Squibb Company (BMY) opened at 55.95 on Friday. The company has a market cap of $91.75 billion, a P/E ratio of 20.43 and a beta of 1.17. The stock’s 50 day moving average is $55.55 and its 200 day moving average is $54.50. Bristol-Myers Squibb Company has a 12 month low of $46.01 and a 12 month high of $75.62. Bristol-Myers Squibb also was the target of some unusual options trading on Thursday. Investors bought 781 put options on the stock. This is an increase of approximately 117% compared to the average daily volume of 360 put options.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 EPS for the quarter, beating the consensus estimate of $0.73 by $0.01. The business had revenue of $5.14 billion during the quarter, compared to analyst estimates of $5.09 billion. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The company’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.69 earnings per share. On average, analysts anticipate that Bristol-Myers Squibb Company will post $2.97 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, August 1st. Shareholders of record on Friday, July 7th were given a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 2.79%. The ex-dividend date of this dividend was Wednesday, July 5th. Bristol-Myers Squibb’s dividend payout ratio is currently 56.73%.

BMY has been the topic of several research analyst reports. BMO Capital Markets cut shares of Bristol-Myers Squibb from a “market perform” rating to an “underperform” rating and set a $47.00 price objective on the stock. in a research report on Wednesday, May 3rd. Robert W. Baird assumed coverage on shares of Bristol-Myers Squibb in a research note on Tuesday, April 25th. They set an “outperform” rating for the company. Jefferies Group LLC reissued a “buy” rating and set a $64.00 target price on shares of Bristol-Myers Squibb in a research note on Monday, June 5th. Vetr raised shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $58.88 price objective for the company in a research note on Monday, June 5th. Finally, BidaskClub lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, July 3rd. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $63.32.

In other news, Director Theodore R. Samuels II acquired 6,000 shares of the stock in a transaction on Wednesday, August 2nd. The stock was acquired at an average price of $55.94 per share, with a total value of $335,640.00. Following the completion of the transaction, the director now owns 18,000 shares of the company’s stock, valued at approximately $1,006,920. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.23% of the company’s stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.